IL22 and ovarian cancer: We hypothesized that the LR-IL-22 gavage would enable a reduction in tumor burden by modifying the tumor microenvironment and, subsequently, improve overall survival in female C57BL/6MUC-1 mice with widespread abdominal syngeneic 2F8cis ovarian cancer by reducing radiation-induced intestinal toxicity, which could potentially facilitate the addition of therapeutic WAI to novel protocols in the management of ovarian cancer.